SCHEMBL2294969

SCHEMBL2294969

CNC[C@H](O)c1ccc(OS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HIF1A Q16665 2/20 0.47
HTR1A P08908 1/20 0.47
THPO P40225 1/20 0.47
BLM P54132 1/20 0.47
NMUR2 Q9GZQ4 1/20 0.47
CYP2C9 P11712 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
MAPT P10636 4/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ADAMTS4 O75173 1/20 0.45
ENPP3 O14638 5/20 0.45
ENPP1 P22413 5/20 0.45
ENPP2 Q13822 3/20 0.44
CYP2D6 P10635 3/20 0.42
SLC6A2 P23975 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297834 1.00 TDP1 (0.49) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2294400 0.88 ALDH1A1 (0.49) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2293023 0.88 ALDH1A1 (0.49) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
Benzene SCHEMBL27711229 0.86 TDP1 (0.47) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
Benzene SCHEMBL27711260 0.86 TDP1 (0.47) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2294869 0.86 TDP1 (0.47) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL27711455 0.86 TDP1 (0.47) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2291477 0.86 TDP1 (0.47) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2294894 0.85 SMN1; SMN2 (0.46) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A
SCHEMBL2294788 0.85 SMN1; SMN2 (0.46) TDP1SMN1; SMN2ALDH1A1KDM4EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US claimed
CN-101228142-A Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation MITSUBISHI TANABE PHARMA CORP (JP) 2008-07-23 CN claimed
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
CN-102120741-A Production method of an optically active compound MITSUBISHI TANABE PHARMA CORP 2011-07-13 CN disclosed
CN-102050820-A Preparation method of compound with optical activity MITSUBISHI TANABE PHARMA CORP 2011-05-11 CN disclosed
EP-2221305-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
EP-2221304-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed
CN-101228142-A Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation MITSUBISHI TANABE PHARMA CORP (JP) 2008-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 TDP1 659/4885SMN1; SMN2 849/4885ALDH1A1 1251/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 TDP1 659/4885SMN1; SMN2 849/4885ALDH1A1 1251/4885
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 TDP1 659/4885SMN1; SMN2 849/4885ALDH1A1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.